Solventum (SOLV) Surpasses Q4 Earnings and Revenue Estimates
Solventum (SOLV) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.5 per share. This compares to earnings of $1.41 per share a year ago.
Solventum beats quarterly estimates on strong demand for surgical products
Medical device maker Solventum on Thursday beat Wall Street estimates for the fourth quarter, helped by strong demand for its wound care and sterilization products.
Curious about Solventum (SOLV) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Solventum (SOLV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Solventum to Post Q4 Earnings: What's in Store for the Stock?
SOLV readies Q4 results amid solid momentum, tariff headwinds, and M&A focus as investors watch margins and growth trends closely.
SOLV Energy: Powering Higher As A Public Business
SOLV Energy surged 20% post-IPO, reflecting optimism about its power infrastructure services and strong 2025 growth projections. Despite a robust backlog and margin gains, the recent revenue declines and lumpy results raise concerns about valuation and sustainability. At $30/share, the stock trades at ~25x earnings and 18x adjusted EBITDA, compared to larger, diversified peers.
SOLV Energy fetches $6 billion valuation in strong Nasdaq debut
SOLV Energy's shares rose 20% in its New York debut on Wednesday, giving the solar and battery storage firm a valuation of $5.98 billion, underscoring a strong rebound in IPO activity in 2026.
SOLV Energy targets $5 billion valuation in US IPO
Solar and battery storage firm SOLV Energy said on Friday it is targeting a valuation of up to $4.99 billion in its initial public offering in the United States.
Are Medical Stocks Lagging Solventum Corporation (SOLV) This Year?
Here is how Solventum (SOLV) and Cronos Group (CRON) have performed compared to their sector so far this year.
SOLV Acquires Acera Surgical to Expand Advanced Wound Care Portfolio
Solventum buys Acera Surgical for $725M upfront to enter tissue matrices, expanding MedSurg and wound care.
Solventum's Self-Help Is Ahead Of Schedule, But Sentiment Is Not
Solventum offers an interesting risk/reward profile, with improving margins, disciplined reinvestment, and potential revenue growth acceleration offsetting modest core revenue growth concerns. The $725M+ Acera Surgical acquisition provides entry into a double-digit growth wound care market, though it introduces operating and sentiment risks. SOLV's 'Transform for the Future' initiative targets $500M annual cost savings, aiming to boost operating margins above 23% by 2028.
Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Solventum Corporation (SOLV) Presents at Stifel 2025 Healthcare Conference Transcript
Solventum Corporation ( SOLV ) Stifel 2025 Healthcare Conference November 12, 2025 11:20 AM EST Company Participants Wayde McMillan - Chief Financial Officer Doug Bartlett Conference Call Participants Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Frederick Wise Stifel, Nicolaus & Company, Incorporated, Research Division Luckily, Wayde is not the Chief Executive Officer. He tells me, I'm not sure.
